arGEN-X advances third therapeutic antibody program into preclinical development
10-Feb-2012 -
arGEN-X announced that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.ARGX-111 is a novel, fully human antibody specific for c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis. c-Met is widely implicated ...
angiogenesis
cell proliferation
human antibodies
+2